Paul G. Richardson, MD, discusses the role of triplet regimens as the current standard of care in newly diagnosed multiple myeloma.
Miami Cancer Institute Summit on Immunotherapies for Hematologic Malignancies
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
3
Datopotamab Druxtecan and ADC Toxicity Management in EGFR-Mutant NSCLC
4
Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC
5